When the mixture is supplied as a concentrated aqueous extract for oral solution formulation, the first unit operation is centrifugal clarification rather than simple dilution. The extract carries suspended tannin–protein complexes, pectin-like polysaccharides, and chlorophyll residues that generate sediment within 8–12 h in low-viscosity finished liquids. Production-scale clarification on a disc stack centrifuge at 6,000–8,000 rpm is followed by a polishing step through 0.45 µm polypropylene depth media. The clarified liquid is then adjusted with citric acid buffer to pH 4.0–5.0 because the phenolic acid fraction and leonurine-related alkaloids in the mixture show accelerated browning above pH 5.5. For multi-dose oral containers, potassium sorbate at 0.1% w/v or sodium benzoate at 0.1% w/v is added only after buffering; benzoic acid can precipitate below pH 3.8. Terminal pasteurisation at 80°C for 30 min is assessed batch-by-batch. If the flavonoid fraction aggregates under heat, aseptic filtration through 0.22 µm polyethersulfone capsules is substituted. The finished oral solution is filled into 500 mL or 1 L HDPE bottles with tamper-evident closures and released under USP <61> and USP <62> microbial limits, USP <51> preservative efficacy for multi-dose packs, and a specific gravity range of 1.02–1.08 g/mL. The terminal finished product is intended for postpartum sows and cows where the mixture is used as an oral or intrauterine aid for retained placenta and endometritis. Published data for the exact pH stability window of this specific multi-herb mixture is limited; pilot-scale challenge tests at pH 3.5, 4.5, and 5.5 are recommended before commercial batching.

What Processing Boundaries Define Aseptic Injectable Production from the Mixture?

Steam sterilisation is evaluated before aseptic filtration because the aqueous extract contains heat-resistant spores from botanical raw material. A terminal cycle of 115°C for 30 min is preferred over 121°C for 15 min when the leonurine marker assay drops by more than 5% during forced degradation. The concentrated liquid is ethanol-precipitated at 60–70% v/v ethanol to remove high-molecular-weight polysaccharides that foul 10 kDa ultrafiltration membranes. After ethanol removal under vacuum at 45–55°C, the retentate is discarded and the permeate is clarified through 0.45 µm followed by 0.22 µm polyethersulfone sterilising-grade filters. Osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or glycerol, and the solution is filled into type II glass vials under nitrogen in an isolator line. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, and pH stability at 2–8°C. The principal production-scale failure mode is filter plugging during the first 500 L batch if ethanol precipitation is shortened; this requires doubling the 0.45 µm cartridge area and reducing the filling line speed from 120 vials/min to 60 vials/min. Injectable use is restricted to intramuscular or intrauterine administration in dairy cattle and sows. The final ampoule or vial label must state that the product contains no preservative, because sterile-filtered herbal injections are not self-preserved.

In feed premix manufacturing, the mixture API is not blended as a dry powder unless a spray-dried carrier is supplied. Liquid extract is sprayed onto a digestible carrier such as rice hull, corncob meal, or calcium carbonate at a ratio of 1:1 to 1:3 w/w. A ribbon mixer with a working volume of 60–80% and a peristaltic pump at 0.5–1.0 L/min gives better homogeneity than a vertical screw conveyor, which can form wet lumps if the spray nozzle is positioned too close to the shaft. The premix is then diluted into final feed at 0.5–2 kg/t, and the target coefficient of variation for the marker compound should remain below 5%. Sampling follows ISO 6497:2002 for animal feeding stuffs, and assay variance is measured across ten withdrawal points. Carryover and cleaning validation are mandatory because the extract contains sticky flavonoid residues that adhere to stainless steel surfaces and can cross-contaminate subsequent batches. The finished 20 kg laminated woven bags are stored below 30°C and at relative humidity below 60% because residual moisture above 0.5% in the carrier can initiate mold growth. This premix application is intended for postpartum lactating sows and dairy cows. The feed formulator must avoid simultaneous use of mineral acids or high-dose choline chloride in the same batch, because acidic microenvironments accelerate phenolic degradation and reduce homogeneity.

Tablet Compression and Disintegration Limits in Herbal Extract Formulations

The spray-dried extract form of the mixture becomes the primary input for veterinary tablets. Spray drying at an inlet temperature of 160–180°C and outlet 70–85°C reduces stickiness, but the resulting powder still absorbs moisture above 55% RH and causes picking on rotary press punch faces. A precompression force of 8–12 kN followed by a main compression force of 18–25 kN on a 12–16 station rotary tablet press is required to prevent capping. The core formula uses 30–50% w/w dried extract, 30–40% microcrystalline cellulose, 10–20% lactose or dicalcium phosphate, 2–5% croscarmellose sodium, and 0.5–1% magnesium stearate. Disintegration testing follows USP <2040> in 900 mL water at 37°C; the limit of 30 min is often exceeded if the extract content rises above 50% because the polysaccharide fraction swells and forms a gel layer. Tablet hardness is monitored under USP <1217> and is typically kept between 40 N and 80 N for film-coated cores. Aqueous film coating with hydroxypropyl methylcellulose at 3–5% weight gain is limited by edge chipping of the extract; a pan speed of 6–10 rpm and inlet air temperature of 50–60°C are used. The terminal product is a 0.5 g or 1 g veterinary tablet for oral administration to cattle and sows, packaged in aluminium/PVC blisters with desiccant.

If Fluidised-Bed Granulation Is Selected for Veterinary Granules

Fluidised-bed granulation is preferred over high-shear granulation when the dried extract has already been milled to a D90 below 150 µm. The extract powder is blended with lactose or maltodextrin and sprayed with a 5–10% w/w aqueous binder solution of povidone K30 in a top-spray fluid bed. Inlet air temperature is maintained at 50–60°C, product temperature at 30–40°C, and atomising air at 1.5–2.5 bar; higher inlet temperatures cause surface crusting of the spray droplets, while lower temperatures raise the final moisture above 5% and cause blocking in sachet filling. The granulation endpoint is determined by sieve retention: 80–90% of the granules should remain between 0.25 mm and 1.0 mm after drying. The dried granules are filled into 2 g or 5 g aluminium foil sachets under nitrogen because the mixture contains reducing phenolics that discolour in the presence of oxygen. The sachet product is used by oral administration to piglets and calves after postpartum complications, and the dissolution test is performed in 0.1 M hydrochloric acid at 37°C with a 50 rpm paddle speed. Process experience indicates that the principal batch failure is bimodal granule size distribution when the spray rate exceeds 50 g/min for a 10 kg batch; this condition produces fine material that segregates into the sachet filler and causes weight variation above 3%.

After the dry extract is milled to a D90 below 150 µm and premixed with 1–2% colloidal silicon dioxide, capsule filling is carried out on a dosator or tamping-pin machine at relative humidity 35–45% and temperature 20–25°C. Hard gelatin capsule shells are selected because the hygroscopic extract releases moisture during storage and can cross-link gelatin if the fill mass water activity exceeds 0.55. A total fill mass of 250 mg or 500 mg is used for companion animals and calves; the extract fraction is usually 40–60% w/w, with the balance composed of lactose, pregelatinised starch, and 0.5–1% magnesium stearate. The powder blend is sieved through a 500 µm screen before filling, and the locking force is checked at the start and every 30 min because extract powder can accumulate in the bushings and increase fill weight variability. The finished capsules are released under USP <905> uniformity of dosage units and USP <711> dissolution, but the dissolution medium must be chosen carefully because the herbal acids show poor solubility in plain water at pH 7.0. Published data for this specific mixture in hard gelatin capsules is limited, so the manufacturer should generate a 0.1 M hydrochloric acid medium profile before setting a routine limit. The capsules are packed in HDPE bottles with a desiccant canister and are not recommended for use in animals with known hypersensitivity to herbal bitters.

Drench Powder Wettability and Hard-Water Dispersion

The water-dispersible powder form is used for oral drenching in sheep, goats, and young cattle, and the limiting parameter is not active content but wetting time. A hammer-milled extract powder with a D90 below 180 µm is blended with lactose monohydrate, sodium citrate, and 2–5% sodium lauryl sulfate to produce a dispersion that wets in less than 60 s in water at 15–20°C. Hard water above 300 mg/L calcium carbonate equivalence causes precipitation of the acidic polyphenol fraction; therefore the formula includes disodium EDTA at 0.05–0.1% w/w. The powder is filled into 1 kg aluminium foil pouches under nitrogen and sealed with heat-seal lacquer because oxygen permeation below 1 cm³/m²·24 h·bar is required to prevent browning. The final drench is prepared by adding the contents of one pouch to 10–20 L of water with continuous agitation for 3–5 min, and the suspension is administered by drench gun within 4 h. The release test includes sieve analysis through 250 µm and 125 µm sieves, loss on drying below 5% by USP <921>, and microbial limits by USP <61>/<62>. This powder is not suitable for intravenous dilution and must not be used with chlorine dioxide sanitisers because oxidative degradation of the alkaloid fraction occurs rapidly.